Dirozalkib
Tier C — Watch / tradeDirozalkib
Targets：ALK, ROS
Indications (approved)：Non-small cell lung cancer
Regional status
Synthetic routes & intermediates2 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| (I)919110-1-a | 93-51-6 | 2-Hydroxy-5-methylanisole |
| (II)919110-1-a | - | 2-Methoxy-4-methyl-6-nitrophenol |
| (III)919110-1-a | - | 5-Methyl-3-nitrobenzene-1,2-diol |
| (IV)919110-1-a | 106-93-4Available | 1,2-Dibromoethane |
| (V)919110-1-a,(V)919110-1-b | 1809036-19-8 | 7-Methyl-5-nitro-2,3-dihydro-1,4-benzodioxine |
| (VI)919110-1-a | - | 6-Bromo-7-methyl-5-nitro-2,3-dihydro-1,4-benzodioxine |
| (VII)919110-1-a | - | 6-Bromo-7-methyl-2,3-dihydro-1,4-benzodioxin-5-amine |
| (VIII)919110-1-a | 1809036-22-3 | 6-Bromo-8-iodo-7-methyl-2,3-dihydro-1,4-benzodioxin-5-amine |
| (IX)919110-1-a,(IX)919110-1-b | 286961-14-6 | (1-tert-Butoxycarbonyl-1,2,3,6-tetrahydropyridin-4-yl)boronic acid pinacol ester |
| (X)919110-1-a | 1809036-23-4 | tert-Butyl 4-(8-amino-7-bromo-6-methyl-2,3-dihydro-1,4-benzodioxin-5-yl)-3,6-dihydropyridine-1(2H)-carboxylate |
| (XI)919110-1-a,(XI)919110-1-b | - | tert-Butyl 4-(8-amino-6-methyl-2,3-dihydro-1,4-benzodioxin-5-yl)piperidine-1-carboxylate |
| (XII)919110-1-a | 761440-16-8Available | 2,5-Dichloro-N-(2-((1-methylethyl)sulfonyl)phenyl)-4-pyrimidinamine |
| (XIII)919110-1-a | 76697-50-2 | 1-Amino-2-(isopropylsulphonyl)benzene |
| (XIV)919110-1-a | 5750-76-5 | 2,4,5-Trichloropyrimidine |
| (XV)919110-1-a | - | tert-Butyl 4-(8-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-6-methyl-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)piperidine-1-carboxylate |
| Code | CAS No. | Intermediate |
|---|---|---|
| (V)919110-1-a,(V)919110-1-b | 1809036-19-8 | 7-Methyl-5-nitro-2,3-dihydro-1,4-benzodioxine |
| (IX)919110-1-a,(IX)919110-1-b | 286961-14-6 | (1-tert-Butoxycarbonyl-1,2,3,6-tetrahydropyridin-4-yl)boronic acid pinacol ester |
| (XI)919110-1-a,(XI)919110-1-b | - | tert-Butyl 4-(8-amino-6-methyl-2,3-dihydro-1,4-benzodioxin-5-yl)piperidine-1-carboxylate |
| (XVI)919110-1-b | - | 7-Methyl-2,3-dihydro-1,4-benzodioxin-5-amine |
| (XVII)919110-1-b | - | 8-Bromo-7-methyl-2,3-dihydro-1,4-benzodioxin-5-amine |
| (XVIII)919110-1-b | - | tert-Butyl 4-(8-amino-6-methyl-2,3-dihydro-1,4-benzodioxin-5-yl)-3,6-dihydropyridine-1(2H)-carboxylate |
Frequently asked questions
What are the approved indications of Dirozalkib?
Approved indications include: Non-small cell lung cancer.
When does the Dirozalkib patent expire?
No public expiry year is available for Dirozalkib yet; this page updates once verified.
How many synthesis routes are recorded for Dirozalkib?
2 synthesis routes are recorded; the shortest is 4 steps with / total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Dirozalkib intermediates?
2 intermediate CAS of Dirozalkib are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.
How do I get a quote for Dirozalkib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-22